BCRX:NSD-BioCryst Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.64

Change

0.00 (0.00)%

Market Cap

USD 2.72B

Volume

2.79M

Avg Analyst Target

USD 16.20 (+10.66%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

BCRX Stock Forecast & Price:
Based on the BioCryst Pharmaceuticals Inc stock forecasts from 6 analysts, the average analyst target price for BioCryst Pharmaceuticals Inc is USD 16.20 over the next 12 months. BioCryst Pharmaceuticals Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of BioCryst Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, BioCryst Pharmaceuticals Inc’s stock price was USD 14.64. BioCryst Pharmaceuticals Inc’s stock price has changed by +4.20% over the past week, +27.42% over the past month and -9.35% over the last year.

About BioCryst Pharmaceuticals Inc (BCRX:NSD)

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMI ...Read More

Company Website : https://www.biocryst.com

Address : 4505 Emperor Boulevard, Durham, NC, United States, 27703

Employees : 358

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.20

52 Week High : 19.99

Short Ratio : 12.23

52 Week Low : 7.61

Shorted Shares : 29,680,214

200 Day Moving Average : 12.90

Shorted Shares Previous Month : 31,456,380

50 Day Moving Average : 11.15

Shares Held By Insiders : 0.96%

Short Percentage : 17.90%

Shares Held by Institutions : 73.99%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

 USD75.53B 24.40 16.33
REGN Regeneron Pharmaceuticals Inc

N/A

 USD68.27B 12.89 9.72
MRNA Moderna Inc

N/A

 USD66.97B 5.32 3.83
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

 USD38.59B 3.11 1.77
SGEN Seagen Inc

N/A

 USD31.38B 55.02 -46.75
RPRX Royalty Pharma Plc

N/A

 USD29.88B 43.33 20.93
ALNY Alnylam Pharmaceuticals Inc

N/A

 USD28.07B N/A -36.52
GMAB Genmab AS

N/A

 USD24.11B 75.33 6.42
ARGX argenx NV ADR

N/A

 USD20.75B N/A -20.02

ETFs Containing BCRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.70% 82% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.70% 82% B- 87% B+
Trailing 12 Months  
Capital Gain -9.35% 81% B- 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.35% 80% B- 56% F
Trailing 5 Years  
Capital Gain 235.01% 88% B+ 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 235.01% 88% B+ 89% B+
Average Annual (5 Year Horizon)  
Capital Gain 70.69% 88% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.69% 88% B+ 93% A
Risk Return Profile  
Volatility (Standard Deviation) 127.97% 16% F 9% F
Risk Adjusted Return 55.24% 93% A 86% B
Market Capitalization 2.72B 91% A- 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 56.59 3% F 2% F
Price / Cash Flow Ratio -19.15 90% A- 82% B-
EV/EBITDA -19.93 96% A 90% A-
Management Effectiveness  
Return on Equity -1,925.37% 1% F 1% F
Return on Invested Capital -59.11% 44% F 17% F
Return on Assets -28.79% 44% F 14% F
Debt to Equity Ratio -547.23% 99% A+ 97% A+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 12.23 13% F 9% F
Short Percent 17.90% 8% F 10% F
Beta 2.20 10% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector